ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ONCASPAR
Leukemias, lymphomas, and other hematologic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

REMOVE SELECTED | COMPARE SELECTED

Drug Name:

ONCASPAR Rx

Generic Name and Formulations:
Pegaspargase 750 IU/mL; soln for IV or IM inj; preservative-free.

Company:
Enzon Pharmaceuticals

e-Prescribe this drug via Surescripts


Therapeutic Use:

Product Resources »
  • Product Information
  • Coupons, Samples & Vouchers
  • Patient Education and Assistance

Indications for ONCASPAR:

First-line acute lymphoblastic leukemia (including patients with asparaginase hypersensitivity).

Adults and Children's Dose:

Give by IV inj over 1–2 hours or by IM inj (max 2mL/inj site). 2500 IU/m2 no more frequently than every 14 days.

Pharmacological Class:

Enzyme.

Contraindications:

History of pancreatitis, serious hemorrhage, or thrombosis with prior L-asparaginase therapy.

Warnings/Precautions:

Have resuscitation equipment available and observe patient for 1 hour post-dose. Monitor coagulation parameters. Discontinue if serious allergic reactions, thrombotic events, or pancreatitis occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.

Adverse Reactions:

Allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, CNS thrombosis, coagulopathy, hyperbilirubinemia, elevated transaminases.

How Supplied:

Single-use vial (5mL)—1